MAP2K7 and myeloproliferative disorder: A successful case [20] of use of the MEK inhibitor Cobimetinib in the treatment of multiple arterial thrombosis in a 71-year-old man with underlying diseases such as hypertension and myeloproliferative neoplasm has been reported.